NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD
Post# of 85
(Total Views: 56)
Posted On: 08/27/2024 5:00:11 PM
NetworkNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Provides Update on Its Response to Extraordinary Request to Provide PAX-101 to Malawi
PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced that the first patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense (“HAT”) in Malawi had been treated with PAX-101, an intravenous form of Suramin. The announcement noted that the Malawi Ministry of Health has informed PaxMedica that, following the treatment, the patient is recovering at home. The Rhodesiense strain of HAT is nearly 100% fatal if not treated promptly, and Suramin is considered the standard of care in Malawi and many East African countries.
“The first use of PAX-101 to treat a critically ill patient with Stage 1 HAT infection is an important milestone for the company following years of investment in the formulation and commercial scale-up of Suramin, the active pharmaceutical ingredient of PAX-101, with the company’s supply chain partners. We were contacted by the government of Malawi after sustained shortages of IV Suramin in the region in the past year, and we could not ignore their pleas for help. Responding to this extraordinary request demonstrates our commitment to provide this essential medicine to some of the world’s most vulnerable people,” said Howard Weisman, CEO of PaxMedica.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced that the first patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense (“HAT”) in Malawi had been treated with PAX-101, an intravenous form of Suramin. The announcement noted that the Malawi Ministry of Health has informed PaxMedica that, following the treatment, the patient is recovering at home. The Rhodesiense strain of HAT is nearly 100% fatal if not treated promptly, and Suramin is considered the standard of care in Malawi and many East African countries.
“The first use of PAX-101 to treat a critically ill patient with Stage 1 HAT infection is an important milestone for the company following years of investment in the formulation and commercial scale-up of Suramin, the active pharmaceutical ingredient of PAX-101, with the company’s supply chain partners. We were contacted by the government of Malawi after sustained shortages of IV Suramin in the region in the past year, and we could not ignore their pleas for help. Responding to this extraordinary request demonstrates our commitment to provide this essential medicine to some of the world’s most vulnerable people,” said Howard Weisman, CEO of PaxMedica.
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://nnw.fm/PXMD
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)PaxMedica Inc. (PXMD) Stock Research Links
Scroll down for more posts ▼